Human colon cancers express carcinoembryonic antigen (CEA). Thus, CEA has been
considered as a potential vaccine target for immune therapy against colon cancer. In this …

Peripheral T-cell tolerance toward human carcinoembryonic self-antigen (CEA) was broken
in CEA-transgenic C57BL/6J mice by an oral CEA-based DNA vaccine. This vaccine …

In preparation for a clinical trial in patients diagnosed with colorectal cancer, a vaccination
strategy targeting the carcinoembryonic antigen (CEA) was evaluated in mice using a GMP …

This study was designed to determine whether the vaccination of genetically modified
dendritic cells (DCs) simultaneously expressing carcinoembryonic antigen (CEA) …

We previously reported that MC32 cells resist carcinoembryonic antigen (CEA) DNA
vaccination by losing their antigen presentation to Ag-specific CTLs in the context of MHC …

Background: Human colorectal cancer cells overexpress carcinoembryonic antigen (CEA).
CEA is a glycoprotein which has shown to be a promising vaccine target for immunotherapy …

A plasmid DNA vaccine, encoding a truncated form of human CEA fused to a T-helper
epitope (CEA66 DNA) was delivered three times intradermally at 2mg or intramuscularly at …

The efficacy of immunization with DNA plasmids for single truncated carcinoembryonic
antigen (CEA) peptide or triple repeated CEA peptides in mice was evaluated. A DNA …

C57BL/6 and BALB/c mice were immunized with two different plasmids (p91023B and
pKCEA66) encoding different forms of the tumor-associated antigen carcinoembryonic …

The feasibility of dendritic cells (DC) for cancer immunotherapy after transfection by
electroporation with mRNA encoding the human carcinoembryonic antigen (CEA) was …